MOL #81935

TITLE PAGE

Vesnarinone suppresses TNFα mRNA expression by inhibiting valosin-containing protein

Kentaro Hotta, Akihiro Nashimoto, Eiji Yasumura, Masafumi Suzuki, Motoki Azuma, Yosuke Iizumi, Daisuke Shima, Ryusuke Nabeshima, Masaki Hiramoto, Akira Okada, Kumiko Sakata-Sogawa, Makio Tokunaga, Takumi Ito, Hideki Ando, Satoshi Sakamoto, Yasuaki Kabe, Shinichi Aizawa, Takeshi Imai, Yuki Yamaguchi, Hajime Watanabe, Hiroshi Handa

Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Kanagawa, 226-8503, Japan

Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan (K.H., A.N., E.Y., M.S., M.A., D.S., R.N., T.I., H.A., S.S., Y.K., K.S-S, M.T. Y.Y., H.H.); Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan (Y.I.); Department of Metabolic Disorder, Research Institute National Center for Global Health and Medicine, Tokyo, Japan (H.M.); Department of Anatomy, Nihon University School of Medicine, Tokyo, Japan (S.A.); Department of Aging Intervention, National Center for Geriatrics and Gerontology, Aichi, Japan (I.T.) and Department of Biotechnology, Graduate School of Engineering, Osaka University, Osaka, Japan (H.W.)

RUNNING TITLE PAGE

A running title:
Vesnarinone inhibits valosin-containing protein

The name, address, telephone and fax numbers, and e-mail address of the corresponding author:

Hiroshi Handa, M.D. and Ph.D.
Graduate School of Bioscience and Biotechnology,
Tokyo Institute of Technology,
4259 Nagatsuda-cho, Midori-ku, Yokohama, 226-8503, Japan
Fax : +81-45-924-5145
Telephone: +81-45-924-5872
e-mail: handa.h.aa@m.titech.ac.jp

The number of text pages : 41 pages
The number of figures: 6 figures
The number of references: 36 references
The number of words in the Abstract: 125 words
The number of words in the Introduction: 548 words
The number of words in the Discussion: 1104 words

A list of nonstandard abbreviations used in the paper:
CHF: congestive heart failure
DOC: deoxycholic acid
FCS: fetal calf serum
HIF: hypoxia inducible factor
HIV: human immunodeficiency virus
IKK: IκB kinase
IL-1β: interleukin-1-beta
NEM: N-ethylmaleimide
NFκB: nuclear factor kappa B
PAGE: polyacrylamide gel electrophoresis
PCR: polymerase chain reaction
PDE3: phosphodiesterase III
PMSF: phenylmethylsulfonyl fluoride
RT-PCR: reverse transcription- polymerase chain reaction
TNFα: tumor necrosis factor alpha
VCP: valosin-containing protein

Abstract

Vesnarinone is a synthetic quinolinone derivative used in the treatment of cardiac failure and cancer. It is also known to cause agranulocytosis as a side effect, which restricts its use, although the mechanism underlying agranulocytosis is not well understood. Here, we show that vesnarinone binds to valosin-containing protein (VCP), which interacts with poly-ubiquitinated proteins and is essential for the degradation of IκBα to activate NFκB. We show that vesnarinone degrade

to VCP impairs the degradation of IκBα and that the impairment of the degradation of IκBα is the result of the inhibition of the interaction between VCP and the 26S proteasome. These results suggest that vesnarinone suppresses NFκB activation by inhibiting the VCP-dependent degradation of poly-ubiquitinated IκBα, resulting in the suppression of TNFα mRNA expression.

Introduction

Vesnarinone

(3,4-dihydro-6-[4-(3,4-dimethosy-benzoyl)-1-piperazinyl]-2(1H)-quinolinone) is a

quinolinone derivative developed as an inotropic agent for the treatment of congestive

heart failure (CHF) (Cavusoglu et al., 1995) by modulating Ca^{2+} channels (Yatani et al.,

1989). Vesnarinone is now known to have other activities, such as immunosuppressive

activity (Matsui et al., 1994; Sato et al., 1995), the inhibition of HIV production, the

reduction of endotoxemic lethality and the suppression of the growth of various tumor

cell lines, including gastric cancer, lung cancer, adenoid squamous carcinoma and

myeloid leukemia (Fujiwara et al., 1997; Nio et al., 1997; Honma et al., 1999; Kubo et

al., 1999; Yokozaki et al., 1999). However, the induction of agranulocytosis has been

reported as a side effect of vesnarinone, thereby representing a limitation of the usage of

vesnarinone (Cohn et al., 1998).

At the molecular level, vesnarinone appears to enhance myocardial

contractility by augmenting sodium-calcium exchange (Yatani et al., 1989), which may

responsible for the treatment of CHF. Vesnarinone is also known to inhibit

phosphodiesterase III (PDE3), resulting in an increase in the cyclic AMP concentration

4

in cells, leading to vasodilation (Itoh et al., 1993).   Although these pharmacological

effects may be related to the treatment of CHF, the molecular basis of the side effect is

not well understood.

Previously, we showed that vesnarinone impairs the production of TNFα in

bone marrow stromal cells, an event that is essential for the differentiation of the cells

into mature granulocytes (Hiramoto et al., 2004; Nabeshima et al., 1997).   These

finding are also supported by another study that showed that vesnarinone suppressed

both the activation of the transcription factor NFκB and the expression of the TNFα

gene, a target of NFκB (Manna and Aggarwal 2000).   These findings raised the

possibility that the inhibition of NFκB signaling by vesnarinone may cause the observed

agranulocytosis.

NFκB is a key transcription factor that regulates many processes, including

the immune response, inflammation and stress responses.   When a cell is not

stimulated, NFκB is sequestered in the cytosol through the formation of a complex with

a member of the IκB family.   However, once the cell is stimulated by factors such as

TNFα and IL-1β, the IκB kinase (IKK) phosphorylates IκB, and phosphorylated IκB is

then ubiquitinated and degraded by the proteasome.   The released NFκB enters the

nucleus and functions as a homo- or heterodimer transcription factor with a member of

the NFκB family.   Genes related to the immune response, inflammation and other

processes are known to be targets of the NFκB transcription factors.

To investigate the mechanism by which vesnarinone inhibits the activation of

NFκB, we attempted to purify a vesnarinone-binding protein with high-performance

affinity magnetic beads (Nishio et al., 2008a; Shimizu et al., 2000), which are powerful

tools for the identification of the molecular targets of many drugs, including

thalidomide (Ito et al., 2010).   Indeed, a valosin-containing protein (VCP) was

identified as a result of our application of this method.   It is thought that VCP plays

important roles in ubiquitin-dependent protein quality control and intracellular

signalling pathways (reviewed in Meyer et al., 2012).

We further showed that VCP is essential for the ubiquitin-dependent

proteasome-mediated degradation of IκBα and that vesnarinone induces the

accumulation of ubiquitinated IκBα resulting in the inhibition of NFκB activation by

preventing the interaction between VCP and the 26S proteasome.

Materials and Methods

Plasmid construction, antibodies, and materials

The human VCP and IκBα cDNAs were subcloned from a LP101 cell cDNA

library into the mammalian expression vector pHyg-EF-2 (Nishizawa et al., 2003).

Vectors encoding the VCP deletion mutants were created by PCR using mutagenic

primers.   Antibodies specific for FLAG (M2, mouse monoclonal, SIGMA), VCP

(mouse monoclonal), IκBα (sc-371, rabbit polyclonal, Santa Cruz Biotechnology),

phosphorylated IκBα (Cell Signaling Technology), actin, and ubiquitin (mouse

monoclonal) were purchased from the indicated suppliers.

Affinity purification of vesnarinone-binding proteins using FG-beads

FG-EGDE beads were prepared as described previously (Nishio et al., 2008b).

The vesnarinone amino derivative was incubated with the FG-EGDE beads in distilled

water for 24 h at 37 ℃.   The vesnarinone amino derivative-fixed FG-EGDE beads

were washed three times with distilled water and stored at 4°C until use.   The LP101

cell membrane extracts (Dignam et al., 1983) were incubated with the vesnarinone

7

amino derivative-fixed beads for 4 h at 4°C, and the beads were then washed three times with binding buffer (10 mM Tris-HCl [pH 7.4], 100 mM NaCl, 1 mM MgCl$_2$, 1 mM CaCl$_2$, 0.2 mM EDTA, 10% glycerol, 0.1% NP-40, 0.5 mM DTT, 1 mM PMSF, 1 μg/ml pepstatin A, and 1 μg/ml leupeptin).　The bound proteins were eluted with Laemmli dye or binding buffer containing the vesnarinone amino derivative.　The eluted proteins were subjected to SDS-PAGE, silver stained and then subjected to in-gel digestion with trypsin.　The peptide fragments were analyzed by quadrupole time-of-flight mass spectrometry, as described previously (Shimizu et al., 2000).

***In vitro* binding assays**

Lysates of 293T cells expressing the VCP mutants were incubated with the vesnarinone amino derivative-fixed FG-EGDE for 4 h at 4°C and washed three times with binding buffer.　The bound proteins were eluted with Laemmli dye and subjected to SDS-PAGE, followed by immunoblotting with an anti-FLAG antibody.

Cell culture, transfection, and VCP knockdown

The 293T cells were maintained in Dulbecco's modified Eagle's medium containing 10% FCS in 5% CO$_2$, and the LP101 cells were maintained in IMDM

8

containing 10% FCS in 5% CO_2. The knockdown of VCP in the 293T cells was

performed using Lipofectamine RNAiMAX (Invitrogen).

Real-Time RT-PCR

The LP101 cells were treated with 5 ng/ml TNFα for 60 min, and the 293T

cells were treated with 10 ng/ml TNFα for 60 min. The total RNAs were then

prepared using Sepasol RNA I Super (Nakalai Tesque). The quantification of the

TNFα or Glyceraldehyde-3-phosphate dehydrogenase mRNA levels was performed

using the QuantiTect SYBR Green reverse transcription PCR master mix (Qiagen).

Coimmunoprecipitation assay and immunoblotting

Lipofectamine 2000 was used to transfect the 293T cells with

pHyg-IκBα-His-FLAG or pcDNA-VCP-His-FLAG. At two days posttransfection, the

cells were treated with 5 μM MG132 for 60 min, followed by stimulation with 10 ng/ml

TNFα for 20 min. The cells were then harvested, washed twice with PBS, and lysed

with RIPA buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% NP-40, 0.5% DOC,

0.1% SDS, 10 mM NEM, 20 mM NaF, 25 μM MG132, 1 mM PMSF, 1 μg/ml pepstatin

A, and 1 μg/ml leupeptin) or NP-40 lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM

NaCl, 0.1% NP-40, 10 mM NEM, 20 mM NaF, 25 μM MG132, 1 mM PMSF, 1 μg/ml

pepstatin A, and 1 μg/ml leupeptin) at 4℃ for 30 min.   The samples were centrifuged

at 20,000 x g at 4℃ for 15 min, and the supernatants were incubated with anti-FLAG

M2 affinity gel (SIGMA) for 2 h at 4℃.   The beads were then washed three times with

the same buffer used as the binding buffer, and the bound proteins were eluted with a

buffer containing the FLAG peptide (SIGMA), subjected to SDS-PAGE, and analyzed

by immunoblotting.

Results

Vesnarinone suppresses the TNFα-induced activation of NFκB

Previously, we reported that vesnarinone inhibits the production and the

secretion of TNFα from human bone marrow stromal LP101 cells (Hiramoto et al.,

2004; Nabeshima et al., 1997), but its molecular mechanisms were remained unclear.

Based on our previous observations, we first examined whether the inhibition of TNFα

secretion in LP101 cells is the result of the reduction of TNFα mRNA expression.

After the treatment of LP101 cells with different concentrations of vesnarinone, the

cells were induced with TNFα and the quantity of newly transcribed TNFα mRNA was

determined by quantitative RT-PCR.   As shown in Figure 1A, the expression of TNFα

mRNA in the LP101 cells was induced by TNFα and reduced by the addition of

vesnarinone in a dose-dependent manner.   These results suggested that the observed

inhibition of TNFα secretion is the result of decreased TNFα mRNA expression caused

by the treatment with vesnarinone.

Next, we used human embryonic kidney 293T cells to examine whether the

reduction of TNFα mRNA expression by vesnarinone is cell-type specific.   A

reduction of the induced TNFα mRNA was also observed in this cell line (Fig. 1B),

suggesting that the vesnarinone-induced reduction of TNFα expression is not restricted

to bone marrow stromal cells.

As NFκB is known to be the major transcription factor regulating TNFα

expression, we next investigated whether vesnarinone inhibits NFκB-dependent

transcription.   A luciferase gene under the control of four tandem repeated NFκB

binding sites was transfected into the 293T cells, and the effects of vesnarinone on the

NFκB-driven reporter gene expression after TNFα treatment was examined.   The

TNFα-induced expression of the reporter gene was inhibited by the treatment with

vesnarinone in a dose-dependent manner (Fig. 1C).   These results suggested that

vesnarinone inhibited NFκB-dependent transcriptional activation.

It is known that NFκB activity is regulated by specific inhibitory subunits, the

IκB proteins, which are degraded by the ubiquitin-proteasome system during NFκB

activation.   If IκB is not properly degraded, NFκB cannot enter the nucleus and fails to

activate NFκB-dependent transcription.   To determine whether the inhibitory effect of

vesnarinone is due to an effect on IκBα degradation, the cytoplasmic level of IκBα

protein was measured by immunoblotting (Fig 1D).   In the absence of vesnarinone, a

reduction of IκBα protein was observed after 15 min of TNFα treatment as expected and

the IκBα signal was recovered by 60 min. However, in the presence of vesnarinone,

the inhibition of IκBα degradation was observed even after TNFα treatment (Fig. 1D).

This result suggested that vesnarinone inhibits the IκBα degradation process.

As it is known that the degradation of IκB is triggered by IKK-mediated

phosphorylation, we next examined whether IκB is phosphorylated after TNFα

treatment. Interestingly, although the phosphorylation of IκBα was detected either in

the presence or absence of vesnarinone at 15 min after the TNFα stimulation, the

amount of phosphorylated IκBα rapidly decreased in the absence of vesnarinone, which

correlated well with the degradation of IκB (Fig. 1D). Conversely, a substantial

amount of phosphorylated IκBα was detected even after TNFα stimulation in the

presence of vesnarinone. This result correlated well with the remaining amount of

IκBα (Fig. 1D). These results suggested that vesnarinone does not inhibit the

phosphorylation of IκBα but does inhibit the degradation of IκB at a specific point

between IκB phosphorylation and degradation.

Identification of vesnarinone-binding proteins

To clarify the molecular mechanisms of the vesnarinone-induced

13

inhibition of NFκB activation, we attempted to purify vesnarinone-binding proteins

directly using high-performance affinity purification (Shimizu et al., 2000).   The

amino derivative of vesnarinone was immobilized on FG beads (Nishio et al., 2008b)

via the epoxy group (Figure 2A) and then used for the purification of

vesnarinone-binding proteins.   The vesnarinone-fixed beads were incubated with

extracts of human bone marrow stromal LP101 cells, and the binding proteins were

directly purified.   A 97 kDa protein was found to bind specifically to the

vesnarinone-fixed beads, and the subsequent quadrupole time-of-flight mass

spectrometry analysis identified the 97 kDa protein as a valosin-containing protein

(VCP) (Fig. 2B).   VCP is a member of the ATPases associated with diverse cellular

activities possessing two ATPase domains and it is known to play a critical role in many

cellular activities such as the ubiquitin-proteasome system, endoplasmic reticulum

associated degradation of proteins, cell cycle, and DNA repair (reviewed in Meyer et al.,

2012).   The binding specificity of VCP to vesnarinone was examined by adding free

vesnarinone to the elution buffer (Fig 2B).   The addition of free vesnarinone led to the

release of VCP from the beads in a concentration-dependent manner, suggesting that

VCP is a vesnarinone-binding protein (Fig. 2B).   The identification of VCP as a

vesnarinone-binding protein was further confirmed by immunoblotting using an

anti-VCP antibody (Fig 2B, bottom), which specifically reacted with the purified 97

kDa protein.   In addition, the recombinant VCP (rVCP) protein overexpressed in *E.*

coli also has the ability to bind to the vesnarinone-fixed beads, as shown in Figure 2C,

indicating that vesnarinone binds to directly VCP.

Determination of the vesnarinone-binding region of VCP

We then determined the vesnarinone-binding region of VCP.   VCP is known

to have two ATPase domains, the D1 and D2 domains, which are followed by the

N-terminal region of the poly-ubiquitin-recognition domain (Dai et al., 1998).   Thus,

we generated a FLAG-His-tagged full-length version and a series of deletion mutants of

VCP that have either one or two ATPase domains and assessed the ability of the

full-length and mutant recombinant VCP derivatives to bind to the beads.   The

full-length and deletion mutants consisting of amino acids 186-806, 1-481 and 149-494,

which contain the D1 ATPase domain, bound to the vesnarinone-fixed beads.   In

contrast, two mutants consisting of residues 454-806 and 1-192, lacking the D1 domain,

did not bind to the beads (Fig. 3).   These results indicated that vesnarinone binds to the

central region of VCP, which corresponds to the D1 ATPase domain. This result raised

the possibility that VCP is required for NFκB activation and that the binding of

vesnarinone to VCP causes a functional alteration in VCP, resulting in the impairment

of NFκB activation.

VCP is required for NFκB-dependent gene activation

If vesnarinone inhibits VCP function, then the effect of vesnarinone should be

similar to that of VCP malfunction. Thus, we knocked down VCP expression using a

VCP-specific siRNA and compared the effect of vesnarinone on the transcriptional

activation of NFκB target genes. A western blot analysis showed that the specific

siRNA reduced the level of VCP protein by >90% at 2-4 days after the siRNA

transfection, whereas it had little effect on the protein level of actin (Fig. 4).

After the induction of the cells with TNFα, the expression of the NFκB target

genes TNFα, IκBα, and A20 was examined by quantitative PCR. When the VCP

expression was knocked down by the VCP-specific siRNA, the induction of TNFα gene

expression was significantly attenuated (Fig. 4B), comparable to the result of the

vesnarinone treatment (Fig. 1). In addition to the attenuation of TNFα, the induced

expression of the other NFκB target genes IκBα and A20 mRNA was also attenuated

(Fig. 4C and D).   These results suggest that both vesnarinone and VCP knockdown

attenuate the expression of NFκB target genes in TNFα-stimulated cells by affecting

NFκB activity.

This result, combined with the finding that phosphorylated IκBα is not

degraded in the presence of vesnarinone (Fig. 1D), prompted us to examine the effect of

the proteasome inhibitor, MG132, which is known to inhibit the activation of NFκB

(Hellerbrand et al., 1998).   When the cells were treated with MG132, the activation

levels of TNFα, IκBα and A20 mRNA induced by TNFα were attenuated (Fig. 4) to the

same level produced by the treatment with VCP siRNA.   These results showed that the

common effect of vesnarinone treatment and VCP knockdown are consistent with

MG132 treatment, suggesting that vesnarinone inhibits the function of VCP, which is

involved in a related proteasome degradation process.

Vesnarinone treatment enhances ubiquitinated IκBα accumulation

Due to the result that vesnarinone attenuates TNFα expression, we

hypothesized that ubiquitinated-IκBα was not degraded, but rather, accumulated in the

presence of vesnarinone or VCP knockdown.   Thus, we examined the effect of

vesnarinone on the accumulation of ubiquitinated IκB protein by performing a transient

transfection of a FLAG-IκBα expression vector in 293T cells.   The cells were

incubated with various concentrations of vesnarinone, followed by

FLAG-immunoprecipitation in a highly stringent buffer to purify and concentrate the

ubiquitinated IκBα, which was detected by immunoblotting using anti-ubiquitin or

anti-IκBα antibodies.

Predictably, the high molecular weight ubiquitinated protein detected using

the anti-ubiquitin antibodies and the high molecular weight IκBα detected using the

anti-IκBα antibodies were both enhanced in a dose-dependent manner by the treatment

with vesnarinone (Fig. 5A, lanes 3-6).   In addition, these signals produced similar

pattern to the MG132 treatment (Fig. 5A, lane 7).   Thus, we concluded that

ubiquitinated IκBα accumulated after the vesnarinone treatment.

As the knockdown of VCP showed similar effects to vesnarinone, we

examined whether the knockdown of VCP can also cause the accumulation of

poly-ubiquitinated IκBα.   As determined by western blotting, the knockdown of VCP

induced the accumulation of ubiquitinated IκBα (Fig. 5B).   These results suggest that

18

VCP is significant for the degradation of IκBα and the activation of NFκB.

Vesnarinone prevents the interaction between VCP and the 26S proteasome

Because VCP is known to bind to ubiquitinated proteins such as such as IκBα,

cyclin E, and HIF1α (Asai et al., 2002; Alexandru et al., 2008; Dai et al., 1998b; Cayli

et al., 2009; Dai and Li, 2001; Yen et al., 2000a) and contributes to their degradation,

we examined whether vesnarinone inhibits the interaction of VCP with ubiquitinated

IκBα or the 26S proteasome.   An expression vector encoding VCP-His-FLAG was

transfected into 293T cells, and a co-immunoprecipitation assay was performed using

an anti-FLAG antibody in the presence of MG132.   As shown in Fig. 6A, in the

presence of MG132, 20S C2, which is a component of the 26S proteasome was

co-immunoprecipitated with VCP-His-FLAG(Fig. 6A, lane 4), whereas 20S C2was not

precipitated without MG132 (Fig. 6A, lane 3).   Interestingly, the quantity of the

co-precipitated 20S C2 was reduced by increasing the amount of vesnarinone.   These

results suggested that vesnarinone inhibits the interaction between FLAG tagged VCP

and proteosomal 20S C2 (Fig. 6A lanes 5-7).

 When FLAG-IκBα-expressing cells were used for the co-immunoprecipitation assay,

both VCP and 20S C2 were co-precipitated. In the presence of vesnarinone, the

quantity of 20S C2 was reduced in a dose-dependent manner, whereas the quantity of

VCP was unchanged. As the total amount of ubiquitinated IκB in the assay was almost

the same, it can be concluded that vesnarinone inhibited the interaction between VCP

and the 26S proteasome but not the interaction between VCP and ubiquitinated IκB.

Although we had tried to analyze the interaction between VCP and endogenous 20S

C2 by co-immunoprecipitation using anti-20S C2 antibody, we failed to detect VCP or

IκB with 20S C2, probably because endogenous proteosomal proteins expression was so

abundant, and content of the VCP-interacted 20S C2 was quite limited in mammalian

cells.

While co-immunoprecipitation assay is limited to show the interaction between VCP

and ubiquitinated IκB, these results suggested that ubiquitinated IκB could interact with

20S C2 by mediating with VCP and that vesnarinone blocks proteosomal degradation of

the ubiquitinated IκB by inhibiting the interaction between VCP and 20S C2.

Discussion

In this study, we showed that one of the molecular targets of vesnarinone is

VCP (valosin-containing protein, also known as p97 and cdc48 in yeast), a member of

the AAA (ATPase-associated with various activities) ATPase family (Dai and Li, 2001).

VCP is known to bind ubiquitinated proteins, such as IκBα, cyclin E, and HIF1α and to

contribute to the ubiquitin-dependent proteasome-mediated degradation of proteins

(Asai et al., 2002; Alexandru et al., 2008; Dai et al., 1998b; Cayli et al., 2009; Dai and

Li, 2001; Yen et al., 2000a).   Vesnarinone induced the accumulation of ubiquitinated

IκBα by inhibiting the interaction between VCP and the 26S proteasome, which was

essential for the degradation of IκBα and the activation of NFκB, implying that

vesnarinone inhibited the function of VCP.

It has been reported that ubiquitinated IκBα remained bound to the

p65-containing complexes in cells treated with a proteasome inhibitor, which also

supports our results and others (Roff et al., 1996; Didonato et al., 1996).   These results

suggested that vesnarinone is an NFκB pathway inhibitor and that vesnarinone

suppresses the activation of NFκB and the expression of TNFα mRNA by inhibiting the

interaction of VCP with the 26S proteasome.   As NFκB is an essential transcription

factor for TNFα activation, it is reasonable that the failure of NFκB activation by

vesnarinone directly affects TNFα activation.   This new finding can explain our

previous data and other results (Manna and Aggarwal 2000) that showed that

vesnarinone inhibits the TNFα activation in IL60 and other cell lines.   Although it was

shown that vesnarinone inhibited the TNFα expression by inhibiting NFκB activation in

a previous study (Manna and Aggarwal 2000), we could explain this inhibition based on

molecular mechanisms, showing that vesnarinone inhibits the IκB degradation mediated

by VCP, which is a novel molecular target of vesnarinone.   One of the important

differences from the previous study is IκB phosphorylation status by vesnarinone

treatment.   While the previous study showed inhibition of IκB phosprylation by

vesnarinone, we could observe IκB phosphorylation even after vesnarinone treatment.

The difference may result of the difference of the cell lines, our finding revealed another

mechanism of NFκB regulation by vesnarinone.

Vesnarinone is an inotropic agent for the treatment of congestive heart failure

with several known modes of action.   For example, vesnarinone is known to augment

sodium-calcium exchange (Yatani et al., 1989), resulting in enhanced myocardial

contractility; to inhibit phosphodiesterase III (PDE3), resulting in an increase of the

cyclic AMP concentration; to increase intracellular calcium ions; to alter sodium and

potassium channels; and to activate the phosphorylation of cell adhesion-related

molecules.   Our results presented here add a new role of vesnarinone to the above list

of effects.

Our study also provides new insight into the regulation of NFκB activity.   As

NFκB is an important transcription factor in immune responses, inflammation, cell

proliferation and other important biological processes, it has been considered as an

important target for drug development.   Many small molecules have been reported to

be inhibitors of NFκB thorough their effects on the NFκB activation process.

One group of small molecule inhibitors targets the activity of NFκB.   For

example, gallic acid is reported to interfere with the binding activity of p65 (Choi et al.,

2009).   Proteasome inhibitors, such as PS-341 and PS-519, are known to inhibit

protease activity directly (Sunwoo et al., 2001).   In addition to the direct inhibition of

the proteasome, the protein degradation pathway prior to proteasome entry is also a

target of many compounds.   For example, benzoquinones and herbimycin are known

inhibitors of IκB kinase activity (Ogino et al., 2004) and sesquiterpene lactones are also

hypothesized to interfere with the IκB kinase (Hehner et al., 1999).   Because

vesnarinone is supposed to inhibit the interaction between VCP and a proteasome

component, it can be placed in a new category and no known chemicals have the same

activity yet. Thus, our study raises the possibility of regulating the NFκB activity by a

new target molecule and VCP can be considered a novel target of anti-inflammation and

immune drugs.

Recently, multiple functions of VCP have been identified (Meyer et al., 2012) ,

including autophagy (Ju et al., 2009), endolysosomal sorting and regulating of proteins

(Ritz et al., 2011), mitochondrial membrane protein turnover (Braun et al., 2006) and

genome stability (Meerang et al., 2011). Although we only suggested the inhibition of

the interaction between VCP and the 26S proteasome by vesnarinone in terms of NFκB

inactivation, vesnarinone might affect many other biological processes within other

cellular contexts. Indeed, the examination of the function of vesnarinone via VCP

within the context of different cells is an intriguing avenue of study. For example, as a

previous study suggests that VCP is required for the degradation of cyclin E, a cell cycle

regulator (Dai and Li, 2001), vesnarinone may influence the proliferation of cancer cells

by regulating the degradation of cyclin E. In fact, vesnarinone inhibits the growth of

several cancer cell lines (Honma et al., 1999; Yokozaki et al., 1999), rising the

possibility that vesnarinone might have anti-tumor activity by affecting the function of

VCP and the degradation of cyclin E.   As VCP is known to have multiple functions,

the refined regulation of VCP may be useful in the development of drugs that will be

used for aspects other than NFκB-related processes.

In this study, we used a high-performance affinity chromatography protocol

developed in our laboratory (Shimizu et al., 2000) and identified VCP as a

vesnarinone-binding protein.   We have previously shown that several drug targets,

including thalidomide, can be identified efficiently (Ito et al., 2010) by using this

technique.   The identification of VCP as a molecular target of vesnarinone might have

been difficult without this technique.

Authorship Contributions

Participated in research design: Yasuaki Kabe, Shinichi Aizawa, Takeshi Imai, Yuki
Yamaguchi, Hiroshi Handa

Conducted experiments: Kentaro Hotta, Akihiro Nashimoto, Eiji Yasumura, Masafumi
Suzuki, Motoki Azuma, Yosuke Iizumi, Daisuke Shima, Ryusuke Nabeshima, Masaki
Hiramoto, Akira Okada, Kumiko Sakata-Sogawa, Makio Tokunaga, Hideki Ando,
Satoshi Sakamoto

Wrote and contributed to the writing of the manuscript: Kentaro Hotta, Takumi Ito,
Hajime Watanabe, Hiroshi Handa

References

Alexandru, G., Graumann, J., Smith, G. T., Kolawa, N. J., Fang, R., and Deshaies, R. J. (2008). UBXD7 binds multiple ubiquitin ligases and implicates p97 in HIF1alpha turnover. *Cell* **134:** 804–816.

Asai T., Tomita Y., Nakatsuka S., Hoshida Y., Myoui A., Yoshikawa H., and Aozasa K. (2002). VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. *Jpn J Cancer Res* **93:** 296-304.

Braun, R. J., Zischka, H., Madeo, F., Eisenberg, T., Wissing, S., Büttner, S., Engelhardt, S. M., Büringer, D., and Ueffing, M. (2006). Crucial mitochondrial impairment upon CDC48 mutation in apoptotic yeast. *J Biol Chem* **281:** 25757–25767.

Cavusoglu, E., Frishman, W. H., and Klapholz, M. (1995). Vesnarinone: A new inotropic agent for treating congestive heart failure. *J Card Fail* **1:** 249–257.

Cayli, S., Klug, J., and Chapiro, J. (2009). COP9 signalosome interacts ATP-dependently with p97/valosin-containing protein (VCP) and controls the

ubiquitination status of proteins bound to p97/VCP. *J Biol Chem* **284:** 34944–34953.

Choi, K.-C., Lee, Y.-H., Jung, M. G., Kwon, S. H., Kim, M.-J., Jun, W. J., Lee, J., Lee, J. M., and Yoon, H.-G. (2009). Gallic acid suppresses lipopolysaccharide-induced nuclear factor-kappaB signaling by preventing RelA acetylation in A549 lung cancer cells. *Mol Cancer Res* **7:** 2011–2021.

Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., Gottlieb, S. O., McGrew, F., DeMets, D. L., and White, B. G. (1998). A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. *N Engl J Med* **339:** 1810–1816.

Dai, R. M., Chen, E., Longo, D. L., Gorbea, C. M., and Li, C. C. (1998). Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. *J Biol Chem* **273:** 3562–3573.

Dai, R. M., and Li, C. C. (2001). Valosin-containing protein is a multi-ubiquitin

chain-targeting factor required in ubiquitin-proteasome degradation. *Nat Cell Biol*

3: 740–744.

DiDonato, J., Mercurio, F., Rosette, C., Wu-li, J.,Suyang, H., Ghosh, S., Karin, M.,

(1996). Mapping of the inducible IkappaB phosphorylation sites that signal its

ubiquitination and degradation. *Mol Cell Biol* **16:** 1295-304.

Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983). Accurate transcription

initiation by RNA polymerase II in a soluble extract from isolated mammalian

nuclei. *Nucleic Acids Res* **11:** 1475–1489.

Fujiwara, H., Arima, N., Otsubo, H., Matsushita, K., Hidaka, S., Arimura, K., Kukita,

T., Yamaguchi, K., and Tanaka, H. (1997). Vesnarinone exhibits antitumor effect

against myeloid leukemia cells via apoptosis. *Exp Hematol* **25:** 1180–1186.

Hellerbrand, C., Jobin, C., Iimuro, Y., Licato, L., Sartor, R. B., and Brenner, D. (1998).

Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome

inhibitors and an IkappaB super-repressor. *Hepatology* **27:** 1285–1295.

Hiramoto, M., Kawakami, Y., Nabeshima, R., Shima, D., Handa, H., and Aizawa, S.
(2004). Identification of differentiation-inducing activity produced by human bone
marrow stromal cell line LP101. *Int J Mol Med* **14:** 867–872.

Honma, Y., Yamamoto-Yamaguchi, Y., and Kanatani, Y. (1999). Vesnarinone and
glucocorticoids cooperatively induce G1 arrest and have an anti-tumour effect on
human non-small cell lung carcinoma cells grown in nude mice. *Br J Cancer* **80:**
96–103.

Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., and
Handa, H. (2010). Identification of a primary target of thalidomide teratogenicity.
Science **327:** 1345–1350.

Itoh, H., Kusagawa, M., Shimomura, A., Suga, T., Ito, M., Konishi, T., and Nakano, T.
(1993). Ca2+(-)dependent and Ca2+(-)independent vasorelaxation induced by
cardiotonic phosphodiesterase inhibitors. *Eur J Pharmacol* **240:** 57–66.

Ju, J.-S., Fuentealba, R. A., Miller, S. E., Jackson, E., Piwnica-Worms, D., Baloh, R. H.,

and Weihl, C. C. (2009). Valosin-containing protein (VCP) is required for

autophagy and is disrupted in VCP disease. *J Cell Biol* **187:** 875–888.

Kubo K, Matsuzaki Y, Kato A, Terai S, O. K. (1999). Antitumor effect of vesnarinone

on human hepatocellular carcinoma cell lines . *Int J Oncol.* **14,** 41–46.

Manna, S. K., and Aggarwal, B. B. (2000). Vesnarinone suppresses TNF-induced

activation of NF-kappa B, c-Jun kinase, and apoptosis. *J Immunol* **164:**

5815–5825.

Matsui, S., Matsumori, A., Matoba, Y., Uchida, A., and Sasayama, S. (1994). Treatment

of virus-induced myocardial injury with a novel immunomodulating agent,

vesnarinone. Suppression of natural killer cell activity and tumor necrosis

factor-alpha production. J Clin Invest **94**: 1212–1217.

Meerang, M., Ritz, D., Paliwal, S., Garajova, Z., Bosshard, M., Mailand, N., Janscak, P.,

Hübscher, U., Meyer, H., and Ramadan, K. (2011). The ubiquitin-selective

segregase VCP/p97 orchestrates the response to DNA double-strand breaks. Nat

Cell Biol **13**: 1376–1382.

Meyer, H., Bug, M., and Bremer, S. (2012). Emerging functions of the VCP / p97

AAA-ATPase in the ubiquitin system. *Nat Cell Biol* **14**: 117–123.

Nabeshima, R., Aizawa, S., Nakano, M., Toyama, K., Sugimoto, K., Kaidow, A., Imai,

T., and Handa, H. (1997). Effects of vesnarinone on the bone marrow stromal

cell-dependent proliferation and differentiation of HL60 cells in vitro. *Exp*

Hematol **25:** 509–515.

Nio, Y., Ohmori, H., Minari, Y., Hirahara, N., Sasaki, S., Takamura, M., and Tamura, K.

(1997). A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits

the in vitro and in vivo growth of human pancreatic cancer cell lines. *Anticancer*

Drugs **8:** 686–695.

Nishio, K., Masaike, Y., Ikeda, M., Narimatsu, H., Gokon, N., Tsubouchi, S.,

Hatakeyama, M., Sakamoto, S., Hanyu, N., Sandhu, A., Kawaguchi H, Abe M,

Handa H. (2008) Development of novel magnetic nano-carriers for high-performance affinity purification. *Colloids Surf B Biointerfaces* **64:** 162–169.

Nishizawa, M., Fu, S.-L., Kataoka, K., and Vogt, P. K. (2003). Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation. *Oncogene* **22:** 7931–7941.

Ogino, S., Tsuruma, K., Uehara, T., and Nomura, Y. (2004). Herbimycin A abrogates nuclear factor-kappaB activation by interacting preferentially with the IkappaB kinase beta subunit. *Mol Pharmacol* **65:** 1344–1351.

Ritz, D., Vuk, M., Kirchner, P., Bug, M., Schütz, S., Hayer, A., Bremer, S., Lusk, C., Baloh, R. H., Lee, H., et al. (2011). Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations. *Nat Cell Biol* **13:** 1116–1123.

Roff, M., Thompson, J., Rodriguez, M. S., Jacque, J., Baleux, F., Arenzana-seisdedos, F., and Hay, R. T. (1996). Role of IκBα Ubiquitination in Signal-induced Activation of NFκB in Vivo. *J Biol Chem* **271:** 7844–7850.

Sato, Y., Matsumori, a, and Sasayama, S. (1995). Inotropic agent vesnarinone inhibits
cytokine production and E-selectin expression in human umbilical vein endothelial
cells. J Mol Cell Cardiol **27:** 2265–2273.

Shimizu, N., Sugimoto, K., Tang, J., Nishi, T., Sato, I., Hiramoto, M., Aizawa, S.,
Hatakeyama, M., Ohba, R., Hatori, H., Yoshikawa, T., Suzuki, F., Oomori, A.,
Tanaka, H., Kawaguchi, H., Watanabe, H., and Handa H. (2000).
High-performance affinity beads for identifying drug receptors. *Nat Biotechnol* **18:**
877–881.

Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N., Crowl Bancroft, C., Sausville, E., Adams,
J., Elliott, P., and Van Waes, C. (2001). Novel proteasome inhibitor PS-341
inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and
angiogenesis in squamous cell carcinoma. *Clin Cancer Res* **7:** 1419–1428.

Yatani A, Imoto Y, Schwartz A, B. A. (1989). New positive inotropic agent OPC-8212
modulates single Ca^{2+} channels in ventricular myocytes of guinea pig . *J*
Cardiovasc Pharmacol **13:** 812–819.

Yen, C. H., Yang, Y. C., Ruscetti, S. K., Kirken, R. A., Dai, R. M., and Li, C. C. (2000).

Involvement of the ubiquitin-proteasome pathway in the degradation of

nontyrosine kinase-type cytokine receptors of IL-9, IL-2, and erythropoietin. *J*

Immunol **165:** 6372–6380.

Yokozaki, H., Ito, R., Ono, S., Hayashi, K., and Tahara, E. (1999). Effect of

3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone

(vesnarinone) on the growth of gastric cancer cell lines. *Cancer Lett* **140:** 121–128.

Footnotes

Figure regends

Figure 1

Vesnarinone inhibits TNFα-induced expression of NFκB target genes

LP101 (A) or 293T (B) cells were preincubated at 37ºC for 12 h with different

concentrations (0-300 μM) of vesnarinone, followed by a 60 min incubation with or

without 10 ng/ml TNFα. The total RNA was prepared and analyzed by reverse

transcription Q-PCR using primers specific for TNFα mRNA. The data represent the

averages +/- S.D. of three independent experiments (*, $P < 0.05$). (C) NFκB-driven and

control reporter plasmids were transfected into 293T cells; 12 h later, the cells were

preincubated with different concentrations (0-300 μM) of vesnarinone for 12 h,

followed by a 12 h incubation with or without 10 ng/ml TNFα. The cells were harvested,

and the cell lysates were subjected to luciferase assays. (D) The 293T cells were

preincubated with or without 300 μM vesnarinone for 12 h and treated with TNFα(10

ng/ml), followed by a 0-60 min incubation. The cells were harvested, and IκBα

phosphorylation was analyzed by immunoblotting (upper panel). Lower graph shows

each band intensity of p-IκB, IαB or 20S C2.

Figure 2

Identification of VCP as a vesnarinone-binding protein

(A) Structure of the vesnarinone amino derivative and FG-beads. (B) Affinity

purification of vesnarinone-binding proteins. Vesnarinone-binding protein was purified

from LP101 cell extracts with vesnarinone immobilized FG-beads (fix-N-Ves). The

bound protein was eluted by increasing concentrations (0-6 mM) of free N-vesnarinone

(free-N-Ves). The eluted proteins were analyzed by silver staining (top) and

immunoblotting (IB) using an anti-VCP antibody. When the free FG-beads were used

(fix-N-Ves -), no specific binding protein was purified. (C) Direct binding of

vesnarinone to VCP. Recombinant VCP-His-FLAG was incubated with

vesnarinone-immobilized FG-beads, and the bound materials were immunoblotted.

Figure 3

Vesnarinone binds to the D1 domain of VCP

(A) Schematic structure of wild-type VCP and its derivatives used for the mutational

study. VCP has an N-terminal poly-ubiquitin recognition domain, the D1-domain and

the D2-domain. The results of the vesnarinone-binding assays are summarized to the

38

right of the structure. (B) His-FLAG-tagged VCP deletion mutants were expressed in

293T cells and purified by using vesnarinone-immobilized beads. The input (left) and

eluted (right) proteins were immunoblotted using an anti-FLAG antibody.

Figure 4

VCP knockdown suppresses the TNFα-induced expression of NFκB target genes

(A) Knockdown of VCP expression by siRNA. The 293T cells transfected with the

VCP- or GFP-specific siRNA were incubated for different time periods (0, 20, 25, 30,

60, 90, 120, 180 min from the left) with 10 ng/ml TNFα, and the cell lysates were

subjected to western blot analysis using anti-VCP and anti-actin antibodies (upper

panel). Lower panel shows each band intensity of VCP or actin. (B-D) The 293T cells

were transfected with VCP-specific siRNA or mock-transfected; 72 h later, the cells

were treated with or without TNFα for 30 min. The total RNA was prepared and

analyzed by reverse transcription Q-PCR using primers specific for the indicated

mRNAs. The data represent the average +/- S.D. of three independent experiments (*, P

< 0.05; **, $P < 0.01$).

Figure 5.

Vesnarinone and VCP knockdown enhance IκBα protein accumulation

(A) Accumulation of polyubiquitinated IκB in vesnarinone-treated cells. Empty vectors

(mock) or pcDNA3.1-FLAG-IκBα were transfected into 293T cells. The cells were then

incubated with different concentrations (0-300 μM) of vesnarinone at 48 h after the

transfection, and the cells were treated with or without 10 ng/ml TNFα for 30 min at 60

h after the transfection. The cell lysates were subjected to immunoprecipitation using an

anti-FLAG antibody. The lysates (input) and immunoprecipitates were immunoblotted.

(B) Accumulation of polyubiquitinated IκB in VCP knockdown cells. The cells were

transfected with VCP-specific siRNA; 24 h later, the cells were transfected with

pcDNA3.1-FLAG-IκBα. After 72 h, the cells were exposed to 10 ng/ml TNFα for 30

min. The cell lysates were subjected immunoprecipitation using an anti-FLAG antibody.

The lysates (input) and immunoprecipitates were immunoblotted.

Figure 6

Vesnarinone inhibits the interaction between VCP and the proteasome.

(A) Empty vector or pHyg-EF2-VCP-His-FLAG was transfected into 293T cells; 48 h later, the cells were treated with different concentrations (0-300 μM) of vesnarinone. Twelve hours later, the cells were treated with 5 μM MG132 for 60 min, followed by stimulation with 10 ng/ml TNFα for 20 min.   The cell lysates were subjected to immunoprecipitation using an anti-FLAG antibody.   The lysates (input) and co-immunoprecipitates (IP:FLAG) were immunoblotted using either anti-FLAG or anti-20S C2. (B) Either an empty vector or pcDNA3.1-FLAG-IκBα was transfected into 293T cells; 48 h later, the cells were treated with different concentrations (0-300 μM) of vesnarinone. Twelve hours later, the cells were treated with or without 10 ng/ml TNFα for 30 min. The cell lysates were subjected to immunoprecipitation using an anti-FLAG antibody. The lysates (input) and co-immunoprecipitates (IP:FLAG) were immunoblotted. Co-immunoprecipitates were detected using anti-VCP, anti-FLAG, anti-20S C2 or anti-ubiquitin antibody.

Figure 1

Figure 2

A

OH   OH
| |
CH—CH₂—N—CH₂—CH—CH₂—O—CH₂—CH₂—O—CH₂—CH—CH₂
                                              \O/

H₂N—CH₂—CH₂—O—CH₂—CH₂—O Vesnarinone amino derivative (N-Ves)

B

| free-N-Ves[mM] | | 0 | 1 | 3 | 6 | 0 | 1 | 3 | 6 |
| fix-N-Ves | Inp | – | – | – | – | + | + | + | + |

Silver Stain
200 –
116 –
97 –   ← VCP
66 –

IB:VCP

      1   2   3   4   5   6   7   8   9

C

              Input (%)   Fixed N-Ves
           0.1   0.3   1   –   +

                                            IB:FLAG

Figure 3

Figure 4

Figure 5

Figure 6